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The linkage of routine data collections are valuable for population-based evaluation of smok-
ing cessation pharmacotherapy in pregnancy where little is known about the utilisation or
safety of these pharmacotherapies antenatally. The use of routine data collections to study
smoking cessation pharmacotherapy is limited by disparities among data sources. This
study developed an algorithm to resolve disparity between the evidence of pharmacother-
apy utilisation for smoking cessation and the recording of smoking in pregnancy, examined
its face validity and assessed the implications on estimates of smoking cessation pharmaco-
therapy utilisation.
Methods
Perinatal records (n = 1,098,203) of women who gave birth in the Australian States of West-
ern Australia and New South Wales (2004–2012) were linked to hospital admissions and
pharmaceutical dispensing data. An algorithm, based on dispensing information about
the type of smoking therapy, timing and quantity of supply reclassified certain groups of
women as smoking during pregnancy. Face validity of the algorithm was tested by examin-
ing the distribution of factors associated with inaccurate recording of smoking status among
women that the algorithm classified as misreporting smoking in pregnancy. Rate of utilisa-
tion among smokers, according to original and reclassified smoking status, was measured,
to demonstrate the utility of the algorithm.
Results
Smoking cessation pharmacotherapy were dispensed to 2184 women during pregnancy, of
those 1013 women were originally recorded as non-smoking as per perinatal and hospital
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data. Application of the algorithm reclassified 730 women as smoking during pregnancy.
The algorithm satisfied the test of face validity—the expected demographic factors of mar-
riage, private hospital delivery and higher socioeconomic status, were more common in
women whom the algorithm identified as misreporting their smoking status. Application of
the algorithm resulted in smoking cessation pharmacotherapy utilisation estimates ranging
from 2.3–3.6% of all pregnancies.
Conclusion
Researchers can use the algorithm presented herein to improve the identification of smok-
ing among women who use cessation pharmacotherapies during pregnancy. Improved
identification can improve the validity of safety analyses of smoking cessation pharmaco-
therapy—providing clinicians with valuable evidence to use when counselling women on the
role of pharmacotherapy for smoking cessation during pregnancy.
Introduction
Smoking in pregnancy is associated with poor maternal and fetal outcomes [1] yet is still rela-
tively common [2, 3]. In 2013, it was estimated that between 11.3% and 15.0% of pregnant
Australian women smoked [2, 3]. Less than half of these women quit spontaneously upon
learning about their pregnancy, indicating that a large proportion are likely to require assis-
tance to quit [4]. Psychosocial interventions have a modest impact on smoking rates during
pregnancy [5]. The effectiveness of psychosocial interventions improves substantially when
provided in combination with smoking cessation pharmacotherapies [6], however little is
known about the safety of these pharmacotherapies in pregnancy [7–10], or the extent to
which they are used by pregnant women [10–13]. Randomised controlled trials of varenicline
or bupropion in pregnancy are unethical, due to limited evidence about their safety [7, 9, 10]
and randomized control trials of nicotine replacement therapy (NRT) have faced difficulties
with recruiting sufficient study participants [14, 15]. Research on utilisation and safety of
smoking cessation pharmacotherapies in pregnancy is therefore largely limited to observa-
tional studies. Several observational studies suggested that during-pregnancy NRT use was not
associated with increased risk of any major birth defects, but these studies reported inconsis-
tent findings about the risk of preterm birth, stillbirth and low birth weight [16–19]. Evidence
regarding the safety of bupropion is limited to a pilot trial and a record linkage study, which
did not find increased risk of adverse outcomes [7, 20]. Evidence regarding the outcomes of
varenicline use is limited to that from case series [10, 21].
Routinely-collected health data are a useful resource, because they allow for large popula-
tion-based studies and reduce possible recall bias present in survey or questionnaire data. One
of the concerns when using routinely collected data for pharmaco-epidemiological studies of
smoking cessation medications is the validity and accuracy of smoking status recording. Esti-
mates of utilisation will be altered by the extent to which the women who are smoking (and
potential therapy users) are captured completely. Likewise, misclassification of smoking status
can lead to inaccurate estimates of risk in safety analyses.
This study therefore focuses on how to optimise the ascertainment of smoking status from
routinely-collected perinatal and hospital data from the Australian States of New South Wales
(NSW) and Western Australia (WA). Previous work has indicated that perinatal data in
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Australia underestimate maternal smoking [22–24], therefore hospital diagnosis codes that
indicate tobacco use in the last 28 days have been used to supplement the perinatal data, result-
ing in increased ascertainment of pregnant women who smoked by 9.6% [25]. Yet even when
combined, these records under-ascertain smoking, compared to expected rates from the Aus-
tralian Population Health Survey [25]. Previous studies in the United States of America [26,
27] and the United Kingdom [28, 29] also report under-ascertainment of smoking in preg-
nancy in population-based data.
This study was a part of the Smoking MUMS (Maternal Use of Medications and Safety)
Study which investigates the utilisation and safety of smoking cessation pharmacotherapies in
pregnancy [30]. We found that for nearly half of pregnant women who used a therapy both
perinatal and hospital data did not indicate that they smoked during pregnancy. Such dispari-
ties could be due to the under-recording of smoking status or successful quitting before preg-
nancy with continued treatment for relapse prevention. This study’s first aim was to develop
an algorithm, based on the pattern of pharmacotherapy supply during pregnancy, which can
be applied to linked population health datasets to improve estimates of smoking in pregnancy
among smoking cessation pharmacotherapy users. Given the absence of a gold standard data
variable to ascertain smoking status in these women, the secondary aim was to examine the
face validity comparing the distribution of factors known to be associated with the misclassifi-
cation of smoking in pregnancy between women who were recorded as smoking in pregnancy
and those whom the algorithm identified as having misreported their smoking status. Finally,
the utility of the algorithm was demonstrated by demonstrating the extent to which it influ-
enced estimates of smoking cessation pharmacotherapy utilisation during pregnancy.
Methods
This is a cohort study design, based on data linked for the Smoking MUMS (Maternal Use
of Medications and Safety] Study. The study comprised 1,098,203 pregnancies, belonging to
724,317 women, with a date of delivery between 1st January 2004 and 31st December 2012, to
ensure that dispensing data were available for the entire gestation and 100-day pre-conception
period.
Data sources and linkages
Data sources, linkages and cleaning for the Smoking MUMS Study have been described else-
where [30, 31]. In brief, this study linked perinatal, hospital and dispensing data from two Aus-
tralian states. Firstly; the NSW Perinatal Data Collection and the WA Midwives Notification
Scheme (collectively referred to as perinatal data). These contain delivery information (of all
live and stillbirths of at least 20 weeks or over 400 grams birthweight), outcomes, demographic
and medical information on the mother, including maternal smoking status. Secondly, this
study used the NSW Admitted Patients Data Collection and the WA Hospital Morbidity Data
Collection (collectively referred to as hospital data) which comprise all hospital separations
(discharges, transfers and deaths), containing diagnoses (up to 55 in NSW and 23 in WA)
which are coded according to the Australian Modification of the International Statistical Clas-
sification of Diseases and Related Problems, 10th revision (ICD-10-AM) [32] based on infor-
mation in the medical record. The final dataset used was the Pharmaceutical Benefits Scheme
data (referred to as dispensing data), which contain a record for every pharmaceutical product
(product name, date of supply and prescription, quantity supplied and strength of therapeutic
ingredient) for which a subsidy is paid under the Australian Commonwealth Government
Pharmaceutical Benefits Scheme (PBS) [33]. Each medication was coded according to the Ana-
tomical Therapeutic Chemical (ATC) classification system [34].
Algorithm for resolving discrepancies in smoking status between dispensing and perinatal data
PLOS ONE | https://doi.org/10.1371/journal.pone.0202999 August 30, 2018 3 / 13
NRT patches, varenicline and bupropion are all available through the PBS if prescribed by a
medical practitioner or nurse practitioner and dispensed in community pharmacies or private
hospitals. Supply of these medicines to inpatients in public hospitals and over-the-counter pur-
chases (applicable only to NRT, which is also available over-the-counter) are not PBS-subsi-
dised and therefore not recorded in the dispensing data.
The linkage of perinatal data to hospital data was performed by the WA Data Linkage
Branch and the NSW Centre for Health Record Linkage, while the Australian Institute of
Health and Welfare linked perinatal to dispensing data. The linkages used probabilistic tech-
niques and the best practice protocol for preserving individual privacy [35]. Quality assurance
data show false-positive and false-negative rates of 0.3% and <0.1%, respectively, for NSW
[36] and both are estimated to be 0.11% for WA [37, 38].
Measures
Identifying smoking cessation pharmacotherapy use in pregnancy. All PBS records
where any of smoking cessation therapies including bupropion (ATC code N07BA02),
varenicline (N07BA03) and NRT patches (N07BA01) was dispensed to a woman at any point
between 100 days prior to conception and date of delivery were identified. The minimum rec-
ommended course for non-pregnant adults is 7 weeks for bupropion, 12 weeks for varenicline
and 8 weeks for NRT. Therefore, a full course required multiple dispensings, of those the earli-
est was referred to as the index supply. Days covered by each supply was calculated by dividing
the dispensed quantity by recommended daily doses (twice daily for varenicline and bupro-
pion [39, 40], and once daily for NRT) [41], then summed to derive the total days of supply to
each woman. Women were defined as using smoking cessation pharmacotherapy during preg-
nancy if: i) any date of supply plus the days covered by that supply resulted in date that was
after the date of conception; or if ii) the date of the index supply plus the total days supplied
was beyond the date of conception.
A lookback period of 100 days prior to pregnancy was chosen to allow detection of a
12-week course of smoking cessation pharmacotherapy with a Medicines Possession Ratio
(MPR) of at least 80%. Date of conception was calculated as the gestational age at birth
(recorded in the perinatal data as number of completed weeks of gestation) subtracted from
date of delivery plus 14 days [30].
Identifying recorded smoking status. Perinatal data contained information that indi-
cated whether women smoked tobacco at any time during pregnancy (prior to 2010 in WA,
prior to 2011 in NSW) or during the first half and during the second half of pregnancy (since
2010 for WA and 2011 for NSW). In hospital data, the presence of an ICD-10-AM diagnosis
code of Z72.0 code indicated current tobacco use, that is, the patient has smoked any amount
of tobacco within the last 28 days [32]. In women who were identified as using a smoking ces-
sation pharmacotherapy during pregnancy, the algorithm classified the mothers as smoking
during pregnancy (Fig 1) if there was as a positive response on any of the smoking items in the
perinatal data or there was a Z72.0 code recorded in any diagnosis field of the hospital separa-
tion record related to the delivery [25]. The remaining women (i.e. all negative responses in
perinatal data and absence of the Z72 code in hospital data) were classified as mothers not
recorded as smoking during pregnancy (Fig 1). If all fields contained a negative or no response,
this was considered as smoking not reported.
Algorithm to reclassify smoking status among women recorded as not smoking. Based
on a conservative approach which recognized that potentially successful quit attempt initiated
pre-conception resulted in successful smoking cessation, the algorithm (Fig 1) used three crite-
ria below to distinguish successful quit attempts from those that were unsuccessful in women
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recorded as not smoking. When all three criteria were met, the non-smoking status as
recorded in perinatal and hospital data was maintained, whilst the remaining women were
reclassified as smoking.
• Timing of index supply: The index supply must have been at least one week (in the case of
varenicline or bupropion), or two weeks (in the case of NRT), prior to conception. NRT is
recommended to be used for two weeks prior to quitting and varenicline and bupropion for
one week before a pre-determined quit date [42].
• Duration of therapy supply: the total days of supplies were equal or longer than the minimum
recommended course (8 weeks for NRT, 7 weeks for bupropion and 12 weeks for vareni-
cline) [42]. Given the unknown safety of smoking cessation pharmacotherapy use in preg-
nancy, it is likely that women who are prescribed a smoking cessation pharmacotherapy for
use during pregnancy are highly nicotine dependent, thus any use less than the minimum
recommended course is unlikely to result in a successful cessation [19].
Fig 1. Application of the algorithm.
https://doi.org/10.1371/journal.pone.0202999.g001
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• Medication adherence: The Medicines Possession Ratio (MPR) was equal to or greater than
80% as per standard practice [43]. The MPR was calculated as:
MPR ¼
Total days of SCP supply
ðDate of the final supply þ days supplied at final supplyÞ   date of index supply
 100
Previous studies conducted among non-pregnant population [44–46] have shown strong
relationship between therapy adherence and both short-term abstinence and long-term quit
success. Whilst there are no studies of varenicline or bupropion adherence in pregnancy spe-
cifically, this relationship holds true for NRT use during pregnancy [47].
Examining the face validity of the algorithm. Descriptive statistics were generated,
followed by unadjusted and adjusted analyses of factors associated with reclassification of
smoking status, in order to test the face validity of the algorithm. Factors used for this test of
face validity were identified from the literature regarding the accuracy of reporting of smok-
ing in pregnancy. Under-reporting of smoking during pregnancy is associated with older
maternal age (over 30 years), being married and having higher socioeconomic status [27, 28,
48–52]. Delivery in a private hospital is associated with less accurate recording of maternal
smoking status in administrative data—it is unknown if this is due to maternal or hospital
factors [25]. In this study, maternal age was obtained from perinatal data while marital status
of NSW and WA mothers was obtained from the hospital data and the perinatal data, respec-
tively. Variables relating to socioeconomic status of the mothers included Socio-Economic
Index For Area (SEIFA) and concessional beneficiary status. The SEIFA Index of Relative
Socio-economic Disadvantage scores for the mothers’ Statistical Local Area of residence
(obtained from perinatal data) were grouped into quintiles [53]. The mother’s concessional
beneficiary status indicated whether she received social welfare due to chronic illness,
disability or low income. This variable was derived from the dispensing data record of smok-
ing cessation pharmacotherapy supply, and categorized as general or concessional. The rela-
tionship between each of these factors and reclassification of smoking status was initially
examined with crude odds ratios (ORs), followed by a single logistic regression in which all
five factors were entered into a single adjusted model. Because several of these variables
related to socioeconomic status, a check for collinearity was performed. Adding each vari-
able to the model one at a time caused no change to the significance of the other variables in
the model.
Examining the impact of the algorithm on smoking cessation pharmacotherapy utilisa-
tion. To examine the impact of the smoking status reclassification on estimates of smoking
cessation pharmacotherapy utilisation, two sets of utilisation estimates for each therapy were
generated. In both sets, the numerator comprised women who smoked during pregnancy and
used smoking cessation pharmacotherapy, and the denominator was the number of women
who smoked during pregnancy. The first set (lower bound estimate) was based on smoking
status that was recorded in perinatal or hospital data while the second set (upper bound esti-
mate) was based on smoking status reclassified by the algorithm. Utilisation was only esti-
mated in pregnancies during which the particular smoking cessation pharmacotherapy was
available. That is, bupropion utilisation was measured in all pregnancies in the cohort (PBS
listed on the 1st of February 2001); varenicline in pregnancies with conception date from 10th
of January 2008 (listing date), and NRT in pregnancies with a conception date from 1st of Feb-
ruary 2011 (listing date) to 31st December 2012 (final delivery date included in cohort). The
use of any smoking cessation pharmacotherapy was restricted to pregnancies with conception
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dates from the 1st of February 2011 to a delivery date of the 31st December 2012, during which
all three smoking cessation pharmacotherapy were available.
All analyses were carried out in SAS version 9.4. Ethical approval for this study was granted
by the NSW Population and Health Services Research Ethics Committee, the Australian Insti-
tute of Health and Welfare Ethics Committee, and the Department of Health WA Human
Research Ethics Committee.
Results
Amongst women who gave birth in NSW and WA between 1st of January 2004 and 31st
December 2012, smoking cessation pharmacotherapy dispensing was identified for 2,184 preg-
nancies (Fig 1). These women received between one and three smoking cessation pharmaco-
therapy supplies (median one) during their pregnancy or the preceding 100 days. Mean
maternal age was 29.2 years, and median parity was one.
In 1,013 (46.4%) of these pregnancies, smoking was not recorded in both perinatal and hos-
pital data. In 6 of these 1013, this was due to a missing, as opposed to negative, response. Of
these 1,013 pregnancies, 482 received the initial smoking cessation pharmacotherapy supply
later than 2 weeks (NRT) or 1week (varenicline and bupropion) prior to conception, and were
therefore re-classified as smoking in pregnancy. Of the remaining 531 with an initial script
prior to the cut-off date, 194 received less than the minimum recommended course of smoking
cessation pharmacotherapy and were reclassified as smoking in pregnancy. Of the remaining
337 who received at least the minimum dose, 54 had an MPR of less than 80% and were reclas-
sified as smoking in pregnancy. This resulted in a total reclassification of 730 pregnancies.
Therefore, after application of the algorithm there were 1,901 (87.0%) mothers who used a
smoking therapy and smoked during pregnancy, and 38.4% of these had no smoking record in
both the hospital and perinatal data.
Factors associated with reclassification of smoking status
As seen in Table 1, there was a greater proportion of women who were married, over 30 years
of age, delivered in private hospitals, lived in the highest SEIFA quintile and were PBS general
patients among the women who were reclassified as smokers, compared to women recorded
as smokers. After adjustment for all variables listed in Table 1, factors significantly associated
with being reclassified included delivery in private hospitals (OR 1.59, 95% CI 1.2–2.5), PBS
general patient status (OR 2.12, 95% CI 1.70–2.61) and being married (OR 1.50 95% CI 1.20–
1.88). This indicates face validity of the algorithm, as women identified by the algorithm as
misreporting their smoking status are be demographically similar to women identified as mis-
reporters in past studies—higher socioeconomic status (non-concessional), married and deliv-
ered in a private hospital.
Prevalence of smoking cessation pharmacotherapy utilisation
Table 2 presents the two sets of estimates of smoking cessation pharmacotherapy utilisation,
stratified by type of smoking cessation pharmacotherapy and years that the smoking cessation
pharmacotherapy was available on the PBS. When measured among the lower bound estimate
prevalence of any smoking cessation pharmacotherapy use in pregnancy was 2.3%. In the
upper bound estimate the prevalence increased to 3.6%, a relative increase of 56.5%. There was
a relative increase in the prevalence of bupropion and varenicline utilization of 0.1% to 0.2%
and 1.0% to 1.8%, respectively, and an increase in the estimate of NRT utilization of 30.8%.
Algorithm for resolving discrepancies in smoking status between dispensing and perinatal data
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Discussion
Among the 2184 pregnancies during which smoking cessation pharmacotherapy were dis-
pensed, 53.6% had maternal smoking recorded in the perinatal or hospital data. After applica-
tion of the algorithm, it was estimated that smoking occurred in 87.0% of pregnancies during
which smoking cessation pharmacotherapy were dispensed. The finding that reclassified
smokers were more likely to be married, have a higher socioeconomic status and to deliver in
a private hospital, than women for whom smoking was recorded, is consistent with previous
studies [25, 48–50, 52]. These findings confirm the face validity of the algorithm.
Table 1. Relationship between factors known to be associated with under-reporting smoking in pregnancy and reclassification of smoking status by the algorithm.






Reclassified smoking in pregnancy
Crude OR (95% CI) Adjusted OR (95% CI)
Maternal age
30 years 500 (42.7) 355 (48.6) 1.27 (1.06–1.53) 1.00 (0.82–1.22)
<30 years 671 (57.3) 375 (51.4) 1.00 1.00
Marital Status
Married 703 (60.0) 551 (75.5) 2.05 (1.67–2.52) 1.50 (1.20–1.88)
Not Married 468 (40.0) 179 (24.5) 1.00 1.00
Socioeconomic Status (SES)
1 (highest SES) 126 (10.9) 152 (21.0) 2.11 (1.53–2.91) 1.39 (0.99–1.97)
2 283 (24.4) 200 (27.6) 1.24 (0.93–1.64) 1.03 (0.77–1.38)
3 300 (25.9) 152 (21.0) 0.89 (0.66–1.19) 0.84 (0.62–1.13)
4 227 (19.6) 93 (12.8) 0.72 (0.52–0.99) 0.69 (0.49–0.96)
5 224 (19.3) 128 (17.7) 1.00 1.00
Hospital Type†
Private 69 (5.9) 105 (14.4) 2.68 (1.95–3.69) 1.59 (1.2–2.5)
Public 1099 (94.1) 623 (85.6) 1.00 1.00
PBS Concessional Status
General 343 (29.3) 394 (54.0) 2.83 (2.34–3.43) 2.12 (1.70–2.61)
Concessional 828 (70.7) 336 (46.0) 1.00 1.00
contain missing data;
† all listed factors were entered simultaneously; bold text signifies statistically significant relationships
https://doi.org/10.1371/journal.pone.0202999.t001
Table 2. Smoking cessation pharmacotherapy utilisation rates.
Smoking cessation pharmacotherapy utilisation




Smoking cessation pharmacotherapy utilisation among pregnancies




NRT in pregnancies from 1st Feb 2011 222 (1.3) 301 (1.7)
Bupropion in pregnancies from 1st Jan
2004
212 (0.1) 325 (0.2)
Varenicline in pregnancies from 10th
Jan 2008
672 (1.0) 1199 (1.8)
Any smoking cessation
pharmacotherapy in pregnancies from
1st Feb 2011
406 (2.3) 656 (3.6)
Year stratification is based on the dates that each medication was available on the PBS
https://doi.org/10.1371/journal.pone.0202999.t002
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Of the total 1901 women found by the algorithm to smoke, 38.4% were not originally
recorded as smoking in pregnancy. This is consistent with evidence that smoking is under-
ascertained in Australian perinatal and hospital data. The magnitude of under-ascertainment
is higher than that found in previous validation studies, but these have used medical records
were used as the gold standard [22, 24]. The medical record is likely to underestimate smoking
in pregnancy as there is no compulsory item on smoking status. It is also likely that there is
genuinely greater under-ascertainment of smoking in pregnancy in the population using
smoking cessation pharmacotherapy; women who have made attempts to quit smoking during
pregnancy are more likely to misreport smoking to medical practitioners [49].
As smoking during pregnancy is under-ascertained in administrative data in a number of
other countries, including the United States of America [26, 27] and the United Kingdom [28,
29], this method is likely to be of value internationally. The extent to which application of this
algorithm will increase the identification of smoking in pregnancy, and therefore improve esti-
mates of smoking cessation pharmacotherapy utilisation and safety, will vary according to the
quality of the administrative data from which smoking in pregnancy is identified.
Whilst this study had access to dispensing data for all women with a perinatal data record,
smoking cessation pharmacotherapy utilisation in pregnancy is typically only measured
amongst women recorded as smoking in pregnancy in administrative data [12, 54]. The
under-identification of smoking in pregnancy therefore has the potential to lead to inaccu-
rate estimates of smoking cessation pharmacotherapy utilisation during pregnancy. As dem-
onstrated in the current study, including undetected smokers in the cohort increases the
prevalence estimate of smoking cessation pharmacotherapy utilisation by a relative 56.5%. It
must be noted that this may be an overestimate, as undetected smokers who use smoking
cessation pharmacotherapy were added to both the numerator and denominator of the esti-
mate, whilst undetected smokers who do not use smoking cessation pharmacotherapy do
not contribute to the denominator. Future studies of smoking cessation pharmacotherapy
utilisation should therefore report both lower and upper bound estimates, to better contextu-
alize the true prevalence.
The possibility of misclassification of smoking status amongst smoking cessation pharma-
cotherapy users has been acknowledged as a limitation in previous studies of smoking cessa-
tion pharmacotherapy safety [17, 18]. This study has indicated that 730 women smoking
during pregnancy would be misclassified as non-smokers in smoking cessation pharmacother-
apy safety analyses, if not identified by the algorithm. As a result, there would be inadequate
control for the confounding effect of smoking on the outcomes examined, and inaccurate esti-
mates of risk associated with smoking cessation pharmacotherapy would eventuate. The algo-
rithm developed in the current study therefore has the potential to improve the accuracy of
estimates of smoking cessation pharmacotherapy safety during pregnancy. By contributing to
improvements in the quality of evidence available, this study may provide clinicians with the
information to better counsel women about the risks and benefits of using smoking cessation
pharmacotherapy during pregnancy.
Finally, this study is an exemplar of innovative use of multiple data sources to ascertain
accurate information about lifestyle factors. This may be lacking from survey or questionnaire
data regarding medications, environmental exposures or lifestyle factors, which iss frequently
subject to recall bias.
Limitations
Despite not being able to conduct a direct validation of the algorithm, the algorithm is based
on expert content knowledge and satisfied a test of face validity. The algorithm is conservative
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in its reclassification of pregnant women’s smoking status, and we are therefore confident that
the women reclassified as smokers were indeed smoking during pregnancy. In contrast, this
conservative approach means that the women classified by the algorithm as not smoking in
pregnancy may include some women who continued to smoke in pregnancy, but whose pat-
tern of smoking cessation pharmacotherapy supply was suggestive of a possible successful quit
attempt. This should be considered by future users of the algorithm.
Furthermore, dispensing data do not capture over-the counter medication purchases, and
NRT is available both through the PBS (only patches are subsidised) and over-the-counter (all
forms). Intermittent forms of NRT are considered safer than patches for use in pregnancy [4].
Yet there is a considerable price difference; in 2016 in Australia, subsidized NRT patches cost
$114.90 or $12.40 (general and concessional patients, respectively) for 12 weeks, whereas 12
weeks of gum or lozenges cost from $336. Furthermore, NRT patches are popular amongst
pregnant women, even when there is no price difference and they are well informed of the
risks [55] [18]. Therefore, we expect that most women in Australia will choose to access the
subsidized form of NRT. Nevertheless, any underestimate in NRT use may affect the algorithm
in two ways. Firstly, women who only purchase over-the-counter NRT are not captured in the
dispensing data, and would be classified as non-smoking cessation pharmacotherapy users
with their smoking status remaining as recorded in the perinatal and hospital data. Secondly,
some women who use both prescription and over-the-counter NRT may incorrectly remain
classified as not smoking in pregnancy.
Finally, the algorithm could incorrectly reassign smoking status if any of the smoking cessa-
tion pharmacotherapy were used for a purpose other than smoking cessation. Bupropion is
also used as an antidepressant in some countries, but is not licensed for use as an antidepres-
sant in Australia. To be accessed through the PBS, the prescribing doctor must seek authority
via phone [56], which ensures that bupropion is only prescribed for smoking cessation. There-
fore, whilst off-label use is possible, it is unlikely to occur in Australia and thus does not pres-
ent an issue.
Conclusion
In many countries, administrative data under-ascertains smoking in pregnancy, which may
compromise the accuracy of smoking cessation pharmacotherapy safety analyses. Using an
algorithm designed to distinguish successful quit attempts from those that were likely to be
unsuccessful, it was found that almost 40% of women using smoking cessation pharmacother-
apy and smoking during pregnancy were not recorded as smoking in perinatal or hospital
data. The algorithm for correcting smoking status has face validity, and enables the user to cal-
culate an upper and lower bound estimate of smoking cessation pharmacotherapy utilisation,
between which the true prevalence is likely to fall. Use of this algorithm in future Australian
and international studies on smoking cessation pharmacotherapy use and safety has the poten-
tial to improve the quality of the evidence available to clinicians, who can, in turn, better sup-
port pregnant women who are attempting to cease smoking in pregnancy.
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Data curation: Kristjana Einarsdóttir, David B. Preen, Alys Havard.
Formal analysis: Lucinda Roper, Duong Thuy Tran, Alys Havard.
Funding acquisition: Kristjana Einarsdóttir, David B. Preen, Alys Havard.
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